Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-940,783
Closed -$24M 617
2025
Q3
$24M Sell
940,783
-4,709,790
-83% -$116M 0.31% 59
2025
Q2
$137M Buy
5,650,573
+2,349,058
+71% +$54.8M 1.54% 11
2025
Q1
$83.7M Buy
3,301,515
+3,035,820
+1,143% +$79.4M 1.17% 17
2024
Q4
$7.05M Buy
265,695
+81,496
+44% +$2.21M 0.12% 115
2024
Q3
$5.33M Sell
184,199
-9,720
-5% -$284K 0.1% 100
2024
Q2
$5.43M Buy
193,919
+13,276
+7% +$366K 0.1% 109
2024
Q1
$5.01M Buy
180,643
+27,249
+18% +$756K 0.09% 141
2023
Q4
$4.42M Sell
153,394
-226,775
-60% -$6.86M 0.07% 129
2023
Q3
$12.6M Sell
380,169
-160,777
-30% -$5.69M 0.22% 86
2023
Q2
$19.8M Buy
540,946
+338,042
+167% +$13.2M 0.36% 65
2023
Q1
$8.28M Sell
202,904
-415,066
-67% -$17.9M 0.17% 97
2022
Q4
$31.7M Buy
617,970
+467,257
+310% +$22.4M 0.82% 33
2022
Q3
$6.59M Buy
150,713
+77,732
+107% +$3.78M 0.19% 95
2022
Q2
$3.83M Sell
72,981
-652,359
-90% -$33.2M 0.12% 129
2022
Q1
$37.6M Buy
725,340
+371,217
+105% +$19.3M 0.98% 25
2021
Q4
$20.9M Buy
354,123
+40,507
+13% +$2.01M 0.55% 48
2021
Q3
$13.5M Buy
313,616
+17,703
+6% +$784K 0.38% 53
2021
Q2
$12.7M Buy
295,913
+187,990
+174% +$7.31M 0.34% 56
2021
Q1
$3.91M Buy
107,923
+104,956
+3,537% +$3.73M 0.12% 121
2020
Q4
$109K Sell
2,967
-642,470
-100% -$23.6M ﹤0.01% 350
2020
Q3
$22.5M Buy
645,437
+420,431
+187% +$14.7M 0.94% 22
2020
Q2
$6.98M Buy
225,006
+119,843
+114% +$4.07M 0.45% 46
2020
Q1
$3.26M Sell
105,163
-698,869
-87% -$23.8M 0.22% 92
2019
Q4
$29.9M Buy
804,032
+227,196
+39% +$8.09M 2.28% 10
2019
Q3
$19.7M Sell
576,836
-51,237
-8% -$1.86M 1.37% 17
2019
Q2
$25.8M Buy
628,073
+142,457
+29% +$5.66M 2.01% 12
2019
Q1
$19.6M Buy
485,616
+477,521
+5,899% +$19.1M 1.61% 17
2018
Q4
$335K Buy
+8,095
New +$336K 0.05% 164

Other funds holding PFE

Ossiam's PFE Position: Q4 2025 in Review

Ossiam sold out of Pfizer (PFE) in Q4 2025, closing a stake of 940,783 shares — an estimated $24M sold.

Ossiam first reported a position in PFE in Q4 2018 and held it in 28 quarters. The position peaked at $137M in Q2 2025. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Ossiam reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Ossiam sold 940,783 Pfizer shares in Q4 2025, an estimated $24M.
  • Ossiam first reported a position in Pfizer in Q4 2018 and held it in 28 quarters.
  • Ossiam's Pfizer position peaked at $137M in Q2 2025.
  • 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Ossiam's 13F filing for Q4 2025, filed 13 Feb 2026.